Loading…
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling thes...
Saved in:
Published in: | ChemMedChem 2008-03, Vol.3 (3), p.435-444 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03 |
---|---|
cites | cdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03 |
container_end_page | 444 |
container_issue | 3 |
container_start_page | 435 |
container_title | ChemMedChem |
container_volume | 3 |
creator | Brenk, Ruth Schipani, Alessandro James, Daniel Krasowski, Agata Gilbert, Ian Hugh Frearson, Julie Wyatt, Paul Graham |
description | To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered.
Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening. |
doi_str_mv | 10.1002/cmdc.200700139 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2628535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70387616</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</originalsourceid><addsrcrecordid>eNqFkctv1DAQxq0K1JbClSPKiVuWcRI_cqlUZfsAhaUSj16QLMcZLy5J3NrZwv73ZNnVUk49zWj8-77x6CPkNYUZBcjemb41swxAANC8PCDHVHJIBZXi2b4X5RF5EeMtQFFIKg_JEZXAC07FMfleY4x-iEmNOgxjYoPvk7MYsW86NyyTzyYgDpuudk3QwWFMrA_JPKyWydxF4x8wrP-OFrjs0IzYbuaoI8aX5LnVXcRXu3pCvl6cf6mu0vrT5fvqrE4NK7IytZIjMstswxmTJctzCTbjVJuWWzBGlEil5tRmtGwyBkxSNEaWRWsbYRDyE3K69b1bNT22Bocx6E7dBdfrsFZeO_X_y-B-qKV_UBnPJMvZZPB2ZxD8_QrjqPrpNOw6PaBfRSUgl4JTPoGzLWiCjzGg3S-hoDaBqE0gah_IJHjz-Gv_8F0CE1BugV-uw_UTdqr6OK8em6dbrYsj_t5rdfipuMgFUzeLS_WB3Swqev1NXeV_AARDqPM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70387616</pqid></control><display><type>article</type><title>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Brenk, Ruth ; Schipani, Alessandro ; James, Daniel ; Krasowski, Agata ; Gilbert, Ian Hugh ; Frearson, Julie ; Wyatt, Paul Graham</creator><creatorcontrib>Brenk, Ruth ; Schipani, Alessandro ; James, Daniel ; Krasowski, Agata ; Gilbert, Ian Hugh ; Frearson, Julie ; Wyatt, Paul Graham</creatorcontrib><description>To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered.
Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.200700139</identifier><identifier>PMID: 18064617</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Chemistry, Pharmaceutical - methods ; Combinatorial Chemistry Techniques - methods ; compound selection ; Databases, Factual ; Drug Design ; high-throughput screening ; kinase inhibitors ; neglected diseases ; Peptide Library ; Pharmaceutical Preparations - analysis ; Pharmaceutical Preparations - chemistry ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Structure-Activity Relationship ; virtual screening</subject><ispartof>ChemMedChem, 2008-03, Vol.3 (3), p.435-444</ispartof><rights>Copyright © 2008 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</citedby><cites>FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27906,27907</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18064617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brenk, Ruth</creatorcontrib><creatorcontrib>Schipani, Alessandro</creatorcontrib><creatorcontrib>James, Daniel</creatorcontrib><creatorcontrib>Krasowski, Agata</creatorcontrib><creatorcontrib>Gilbert, Ian Hugh</creatorcontrib><creatorcontrib>Frearson, Julie</creatorcontrib><creatorcontrib>Wyatt, Paul Graham</creatorcontrib><title>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered.
Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.</description><subject>Chemistry, Pharmaceutical - methods</subject><subject>Combinatorial Chemistry Techniques - methods</subject><subject>compound selection</subject><subject>Databases, Factual</subject><subject>Drug Design</subject><subject>high-throughput screening</subject><subject>kinase inhibitors</subject><subject>neglected diseases</subject><subject>Peptide Library</subject><subject>Pharmaceutical Preparations - analysis</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>virtual screening</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNqFkctv1DAQxq0K1JbClSPKiVuWcRI_cqlUZfsAhaUSj16QLMcZLy5J3NrZwv73ZNnVUk49zWj8-77x6CPkNYUZBcjemb41swxAANC8PCDHVHJIBZXi2b4X5RF5EeMtQFFIKg_JEZXAC07FMfleY4x-iEmNOgxjYoPvk7MYsW86NyyTzyYgDpuudk3QwWFMrA_JPKyWydxF4x8wrP-OFrjs0IzYbuaoI8aX5LnVXcRXu3pCvl6cf6mu0vrT5fvqrE4NK7IytZIjMstswxmTJctzCTbjVJuWWzBGlEil5tRmtGwyBkxSNEaWRWsbYRDyE3K69b1bNT22Bocx6E7dBdfrsFZeO_X_y-B-qKV_UBnPJMvZZPB2ZxD8_QrjqPrpNOw6PaBfRSUgl4JTPoGzLWiCjzGg3S-hoDaBqE0gah_IJHjz-Gv_8F0CE1BugV-uw_UTdqr6OK8em6dbrYsj_t5rdfipuMgFUzeLS_WB3Swqev1NXeV_AARDqPM</recordid><startdate>20080314</startdate><enddate>20080314</enddate><creator>Brenk, Ruth</creator><creator>Schipani, Alessandro</creator><creator>James, Daniel</creator><creator>Krasowski, Agata</creator><creator>Gilbert, Ian Hugh</creator><creator>Frearson, Julie</creator><creator>Wyatt, Paul Graham</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080314</creationdate><title>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</title><author>Brenk, Ruth ; Schipani, Alessandro ; James, Daniel ; Krasowski, Agata ; Gilbert, Ian Hugh ; Frearson, Julie ; Wyatt, Paul Graham</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Chemistry, Pharmaceutical - methods</topic><topic>Combinatorial Chemistry Techniques - methods</topic><topic>compound selection</topic><topic>Databases, Factual</topic><topic>Drug Design</topic><topic>high-throughput screening</topic><topic>kinase inhibitors</topic><topic>neglected diseases</topic><topic>Peptide Library</topic><topic>Pharmaceutical Preparations - analysis</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>virtual screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brenk, Ruth</creatorcontrib><creatorcontrib>Schipani, Alessandro</creatorcontrib><creatorcontrib>James, Daniel</creatorcontrib><creatorcontrib>Krasowski, Agata</creatorcontrib><creatorcontrib>Gilbert, Ian Hugh</creatorcontrib><creatorcontrib>Frearson, Julie</creatorcontrib><creatorcontrib>Wyatt, Paul Graham</creatorcontrib><collection>Istex</collection><collection>Wiley Online Library</collection><collection>Wiley Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brenk, Ruth</au><au>Schipani, Alessandro</au><au>James, Daniel</au><au>Krasowski, Agata</au><au>Gilbert, Ian Hugh</au><au>Frearson, Julie</au><au>Wyatt, Paul Graham</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2008-03-14</date><risdate>2008</risdate><volume>3</volume><issue>3</issue><spage>435</spage><epage>444</epage><pages>435-444</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered.
Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>18064617</pmid><doi>10.1002/cmdc.200700139</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1860-7179 |
ispartof | ChemMedChem, 2008-03, Vol.3 (3), p.435-444 |
issn | 1860-7179 1860-7187 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2628535 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Chemistry, Pharmaceutical - methods Combinatorial Chemistry Techniques - methods compound selection Databases, Factual Drug Design high-throughput screening kinase inhibitors neglected diseases Peptide Library Pharmaceutical Preparations - analysis Pharmaceutical Preparations - chemistry Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Structure-Activity Relationship virtual screening |
title | Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A24%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lessons%20Learnt%20from%20Assembling%20Screening%20Libraries%20for%20Drug%20Discovery%20for%20Neglected%20Diseases&rft.jtitle=ChemMedChem&rft.au=Brenk,%20Ruth&rft.date=2008-03-14&rft.volume=3&rft.issue=3&rft.spage=435&rft.epage=444&rft.pages=435-444&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.200700139&rft_dat=%3Cproquest_pubme%3E70387616%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70387616&rft_id=info:pmid/18064617&rfr_iscdi=true |